Skip to content

Study of Ferric carboxymaltose in pregnant women lacking iron

Efficacy and Safety of Ferric Carboxymaltose Injection in Iron deficiency anemia in Pregnancy: A Prospective Observational Study

Status
Active, not recruiting
Phases
Phase 4
Study type
Observational
Source
CTRI
Registry ID
CTRI/2021/10/037314
Enrollment
50
Registered
2021-10-13
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O990- Anemia complicating pregnancy, childbirth and the puerperium

Interventions

Intervention1: NIL: NIL

Sponsors

Dr Girija Wagh
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Pregnant women more than 18 years of age visiting to department of Obstetrics and Gynecology of gestational age between 16-36 weeks 2. Pregnant women with hemoglobin (Hb) level more than 6 and less than 10 g/dl. 3. Pregnant women not responding to oral Iron or oral iron therapy not tolerable or oral iron therapy is inappropriate based on clinical judgment of investigator 4. Pregnant women ready to give informed consent for participation in study.

Exclusion criteria

Exclusion criteria: 1. Any other type of anemia other than Iron Deficiency anemia 2. Evidence of iron overload conditions (e.g. hemochromatosis/hemosiderosis). 3. Prior history of allergic reaction to IV iron 4. Significant cardiovascular disease (including myocardial infarction during the 6 months prior to study inclusion, congestive heart failure NYHA Class III or IV and poorly controlled hypertension) 5. Uncontrolled endocrinological or metabolic disorders including uncontrolled hyperparathyroidism. 6. Presence of any active infection 7. Known case of malignancy 8. Presence of active liver disease / HBV or HCV infection, HIV infection / AIDS, asthma, or rheumatoid arthritis 9. Treatment with IV Iron preparations or any investigational drug within 4 weeks prior to study enrollment 10. Any condition that, in the opinion of the investigator, does not justify the patientâ??s inclusion in the study

Design outcomes

Primary

MeasureTime frame
Mean change in hemoglobinTimepoint: At baseline, 4 weeks and 6 weeks

Secondary

MeasureTime frame
Adverse effectsTimepoint: During the study duration;Fatigue measurement by Linear Analogue Scale AssessmentTimepoint: At baseline, 2 weeks, 4 weeks, and 6 weeks;Mean change in hematological parameters (PCV, MCV, MCH, MCHC)Timepoint: At baseline, 4 weeks, and 6 weeks;Mean change in serum ferritin levelTimepoint: At baseline, 4 weeks, and 6 weeks

Countries

India

Contacts

Public ContactDr Girija Wagh

Bharati Vidyapeeth (Deemed To Be University) Medical College, Pune

dr.waghgirija@gmail.com9422000584

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026